The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index; none of the 53 sources its claims cite is checked for support yet.
Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders
Open accessAbstract
OBJECTIVE: To make recommendations on the assessment and management of tics in people with Tourette syndrome and chronic tic disorders. METHODS: A multidisciplinary panel consisting of 9 physicians, 2 psychologists, and 2 patient representatives developed practice recommendations, integrating findings from a systematic review and following an Institute of Medicine-compliant process to ensure transparency and patient engagement. Recommendations were supported by structured rationales, integrating evidence from the systematic review, related evidence, principles of care, and inferences from evidence. RESULTS: Forty-six recommendations were made regarding the assessment and management of tics in individuals with Tourette syndrome and chronic tic disorders. These include counseling recommendations on the natural history of tic disorders, psychoeducation for teachers and peers, assessment for comorbid disorders, and periodic reassessment of the need for ongoing therapy. Treatment options should be individualized, and the choice should be the result of a collaborative decision among patient, caregiver, and clinician, during which the benefits and harms of individual treatments as well as the presence of comorbid disorders are considered. Treatment options include watchful waiting, the Comprehensive Behavioral Intervention for Tics, and medication; recommendations are provided on how to offer and monitor these therapies. Recommendations on the assessment for and use of deep brain stimulation in adults with severe, treatment-refractory tics are provided as well as suggestions for future research.
Overview
CoChat Summary
TL;DR
This AAN practice guideline summary presents 46 recommendations for assessing and managing tics in people with Tourette syndrome and chronic tic disorders, emphasizing individualized, collaborative care and comorbidity screening. Treatment options include watchful waiting, CBIT, medications, botulinum toxin, cannabis-based medication, and DBS for severe refractory tics.
Key findings
- The panel made 46 recommendations; treatment should be individualized and chosen collaboratively among patient, caregiver, and clinician, considering benefits, harms, and comorbid disorders.
- Counseling recommendations note tics begin in childhood, wax and wane, and peak severity usually occurs between ages 10 and 12; in one longitudinal study, 18% of adolescents older than 16 years had no tics and 60% had minimal or mild tics 6 years after initial examination. Watchful waiting is acceptable when tics cause no functional impairment, and CBIT may be an initial option if the patient is motivated.
- Comorbidity screening is recommended: ADHD prevalence in TS ranges from 30% to 50%, and comorbid OCD diagnosis is made in 10%–50%; clinicians should screen for ADHD, OCD, anxiety, mood, and disruptive behavior disorders, and must inquire about suicidal thoughts and attempts.
- Treatment recommendations include CBIT as an initial option relative to medication; α2 agonists, antipsychotics, botulinum toxin, topiramate, cannabis-based medications, and DBS for severe, treatment-refractory tics; DBS of the anteromedial globus pallidus is probably more likely than sham stimulation to reduce tic severity, and treatments infrequently result in complete cessation of tics.
Methods
- A multidisciplinary panel of 9 physicians, 2 psychologists, and 2 patient representatives developed practice recommendations, integrating findings from a systematic review and following an Institute of Medicine-compliant process.
- Recommendations were supported by structured rationales using premises labeled EVID, PRIN, RELA, and INFER; levels A, B, and C corresponded to “must,” “should,” and “may,” assigned via a modified Delphi process with 3 rounds of anonymous online voting.
- This article presents the guideline’s recommendations and suggestions for future research; the complete unabridged guideline is available as a data supplement, and a companion article summarizes the systematic review findings.
Limitations
- Stated: This article focuses on recommendations and does not include detailed analysis of the systematic review; readers are urged to review the unabridged guideline for full assessment.
- Stated: DBS evidence is limited by few operations per year even in expert centers, limited randomized trial information, no consensus on optimal brain target, and methodologic concerns in the largest randomized trials; there is little information on DBS effects on psychiatric comorbidities or efficacy in children.
- Evident from text: Recommendations are based not only on systematic review evidence but also on principles of care, related evidence, and inferences; many recommendations are Level B or C, and several treatments have insufficient evidence for relative efficacy or specific comparisons.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 5 Not valid · 43 Not checked · 48 Own results and interpretations
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The effect size for CBIT appears similar to effect sizes for medications (EVID).”
§ Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders > Behavioral treatments Rationale
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Topiramate is possibly more likely than placebo to reduce tic severity (EVID).”
§ Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders > Topiramate for the treatment of tics Rationale
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“DBS of the anteromedial globus pallidus is probably more likely than sham stimulation to reduce tic severity (EVID).”
§ Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders > Deep brain stimulation (DBS) for tics in the setting of TS Rationale
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“People with tics receiving CBIT are more likely than those receiving psychoeducation and supportive therapy to have reduced tic severity (EVID).”
§ Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders > Behavioral treatments Rationale
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Case reports and case series have comprised the majority of the outcomes data on the efficacy of DBS for TS.”
§ Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders > Suggestions for future research
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims
Create a free account to see all 96 claims and every source verdict.
- It may state two separate claims as one. 25
- Probably not a substantial claim. 16
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“RCTs of BT and RCTs of PT show roughly comparable effect sizes for both treatments (e.g. 0.57–0.68 for CBIT/HRT compared to PST, and 0.45–0.79 for various compounds of PT compared to placebo) [11, 77].”
From European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part II: psychological interventions (2022) · cites this paper as [11]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite psychoeducation being described in clinical guidelines as a first important step of any treatment for TS [5, 11], evidence on what specific elements should be addressed is lacking.”
From European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part II: psychological interventions (2022) · cites this paper as [11]
Experimental — accuracy not yet measuredIn the citing paper
“The AAN guidelines specify that clinicians should offer CBIT as an initial treatment option prior to other psychological interventions and to pharmacotherapy (PT).”
From European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part II: psychological interventions (2022) · cites this paper as [11]
In the citing paper
“Recently, the American Academy of Neurology (AAN) published their clinical guidelines for the treatment of tic disorders, again recommending BT as a first-line intervention for tic disorders.”
From European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part II: psychological interventions (2022) · cites this paper as [11]
In the citing paper
“If CBIT is unavailable, ERP may be an acceptable alternative.”
From European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part II: psychological interventions (2022) · cites this paper as [11]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E. A., & Wright, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611618 · Cited by 1,711
Hirschtritt, M. E., Lee, P. C., Pauls, D. L., Dion, Y., Grados, M. A., Illmann, C., King, R. A., Sandor, P., McMahon, W. M., Lyon, G. J., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2650 · Cited by 770
Prevalence of Tic Disorders: A Systematic Review and Meta-Analysis
Knight, T., Steeves, T., Day, L., Lowerison, M., Jette, N., & Pringsheim, T. (2012) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2012.05.002 · Cited by 543
Self-citationBloch, M. H., Peterson, B. S., Scahill, L., Otka, J., Katsovich, L., Zhang, H., & Leckman, J. F. (2006) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.160.1.65 · Cited by 458
Okun, M. S., Tagliati, M., Pourfar, M., Fernandez, H. H., Rodriguez, R. L., Alterman, R. L., & Foote, K. D. (2005) · Archives of Neurology · doi:10.1001/archneur.62.8.noc40425 · Cited by 425
Self-citationEfficacy and safety of topiramate on weight loss: a meta‐analysis of randomized controlled trials
Kramer, C. K., Leitão, C. B., Pinto, L. C., Canani, L. H., Azevedo, M. J., & Gross, J. L. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00846.x · Cited by 323
SUKHODOLSKY, D. G., SCAHILL, L., ZHANG, H., PETERSON, B. S., KING, R. A., LOMBROSO, P. J., KATSOVICH, L., FINDLEY, D., & LECKMAN, J. F. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200301000-00016 · Cited by 305
Tourette syndrome deep brain stimulation: A review and updated recommendations
Schrock, L. E., Mink, J. W., Woods, D. W., Porta, M., Servello, D., Visser‐Vandewalle, V., Silburn, P. A., Foltynie, T., Walker, H. C., Shahed‐Jimenez, J., et al. (2015) · Movement Disorders · doi:10.1002/mds.26094 · Cited by 282
Self-citation
Research works printed but not linked: 1
- Alaven. Reglan Product Monograph. Stockholm; Alaven: 2010.
Cited by
Mental Health Surveillance Among Children — United States, 2013–2019
Bitsko, R. H., Claussen, A. H., Lichstein, J., Black, L. I., Jones, S. E., Danielson, M. L., Hoenig, J. M., Davis Jack, S. P., Brody, D. J., Gyawali, S., et al. (2022) · MMWR Supplements · doi:10.15585/mmwr.su7102a1 · Cited by 1,723
Andrén, P., Jakubovski, E., Murphy, T. L., Woitecki, K., Tarnok, Z., Zimmerman-Brenner, S., van de Griendt, J., Debes, N. M., Viefhaus, P., Robinson, S., et al. (2022) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-021-01845-z · Cited by 225
Self-citationTourette syndrome: clinical features, pathophysiology, and treatment
Johnson, K. A., Worbe, Y., Foote, K. D., Butson, C. R., Gunduz, A., & Okun, M. S. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00303-9 · Cited by 202
Self-citationRoessner, V., Eichele, H., Stern, J. S., Skov, L., Rizzo, R., Debes, N. M., Nagy, P., Cavanna, A. E., Termine, C., Ganos, C., et al. (2022) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-021-01899-z · Cited by 197
Self-citationA Comprehensive Review of Tic Disorders in Children
Ueda, K., & BLACK, K. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112479 · Cited by 190
Metadata
- Authors
- Pringsheim, T., Okun, M. S., Müller-Vahl, K., Martino, D., Jankovic, J., Cavanna, A. E., Woods, D. W., Robinson, M., Jarvie, E., Roessner, V., Oskoui, M., Holler-Managan, Y., & Piacentini, J.
- Affiliations
- University of Calgary (CA)
- University of Florida Health (US)
- From the Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences (T.P., D.M.), Cumming School of Medicine, University of Calgary, Alberta, Canada; Departments of Neurology and Neurosurgery (M.S.O.), Fixel Center for Neurological Diseases, University of Florida, Gainesville; Department of Psychiatry, Social Psychiatry, and Psychotherapy (K.M.-V.), Hannover Medical School, Germany; Department of Neurology (J.J.), Baylor College of Medicine, Houston, TX; Department of...
- Baylor College of Medicine (US)
- ORCID
- Venue
- Neurology
- Published
- 2019-05-07
- Volume
- 92
- Issue
- 19
- Pages
- 896-906
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC6537133
- OpenAlex
- W2944778893
- Semantic Scholar
- 0ab0dbbd32db2353844679210d20bb0425437faa
- Cited by
- 565
- References
- 52
- Citations by year
- 2026: 89 · 2025: 99 · 2024: 70 · 2023: 77 · 2022: 80 · 2021: 71 · 2020: 62 · 2019: 16
- FWCI
- 59.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- e-Publications@Marquette (Marquette University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- Eli Lilly and Company
- Biogen
- Teva Pharmaceutical Industries
- International OCD Foundation
- McGill University
- Tourette Association of America
- Cytokinetics
- AveXis
- Adamas Pharmaceuticals
- TLC Foundation for Body-Focused Repetitive Behaviors
- Child Mind Institute
- York University
- University of Oxford
- European Commission
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Eisai
- Karolinska Institutet
- Hospital for Sick Children
- Kids Brain Health Network
- Cerebral Palsy Alliance
- Allergan
- UCB Pharma
- Cilag
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Social Sciences › Psychology › Clinical Psychology › Stuttering Research and Treatment
- Keywords
- Tourette syndrome, chronic tic disorders, tic disorders, Comprehensive Behavioral Intervention for Tics, deep brain stimulation, comorbidities, psychoeducation, expectant management, medication, collaborative decision-making
- MeSH terms
- Systematic Reviews as Topic, Behavior Therapy, Counseling, Tourette Syndrome, Humans, Tic Disorders, Tics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-17, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-17 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. https://app.cochat.ai/papers/10.1212/wnl.0000000000007466
- The paper
- Pringsheim, T., Okun, M. S., Müller-Vahl, K., Martino, D., Jankovic, J., Cavanna, A. E., Woods, D. W., Robinson, M., Jarvie, E., Roessner, V., Oskoui, M., Holler-Managan, Y., & Piacentini, J. (2019). Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. https://doi.org/10.1212/wnl.0000000000007466
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.